The Valley Desk

NCT06660355 · Interventional trial

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Overall registry status Recruiting

Phase 2

Conditions Chronic Graft-versus-host Disease (cGVHD)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov